权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting M. catarrhalis for Prevention and Treatment of Otitis Media

针对卡他莫拉菌预防和治疗中耳炎

基本信息

批准号：
9915881
负责人：
Anthony A Campagnari
金额：
$ 39.8万
依托单位：
STATE UNIVERSITY OF NEW YORK AT BUFFALO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-01 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9915881
关键词：
Active Immunization Acute Adherence Adult Antibiotic Resistance Antibiotics Area Bacteria Child Chinchilla (genus)Chronic Chronic Disease Complex Development Disease Environment Goals Health Care Costs Healthcare Systems Host Defense Human Immune system Immunization In Vitro Incidence Infant Infection International Lead Learning Learning Skill Life Lung diseases Metabolic Clearance Rate Microbial Biofilms Modeling Modification Moraxella catarrhalis Morbidity - disease rate Mucous Membrane Nontypable Haemophilus influenza Office Visits Operative Surgical Procedures Otitis Media PUVA Photochemotherapy Physiological Prevention Published Comment Recurrence Recurrent disease Reporting Research Research Project Grants Resistance development Risk Role School-Age Population Sinusitis Source Speech Development Streptococcus pneumoniae Stress Structure Surface Testing Time Treatment Protocols Tympanostomy Tube Insertions Vaccine Antigen antimicrobial bactericide design effective therapy experience hearing impairment human pathogen in vivo interest middle ear middle ear disorder novel novel therapeutic intervention novel therapeutics ototoxicity pathogen pediatrician polymicrobial biofilm prevent public health relevance response symposium therapy design

项目摘要

DESCRIPTION (provided by applicant): Moraxella catarrhalis, a Gram-negative bacterial mucosal pathogen, is a significant cause of middle ear infections (otitis media (OM)) and sinusitis in infants and children and an important source of exacerbations in adults with lung disease. Approximately 80% of all children under 3 will experience at least one episode of OM and many experience recurrent disease, which may result in hearing impairment and developmental/learning problems. OM is a significant source of direct and indirect health care costs and M. catarrhalis is responsible for 3 to 4 million pediatrician office visits annually. Chronic or recurrent OM is now considered a biofilm disease and there have been numerous reports demonstrating that M. catarrhalis forms biofilms in vivo. Biofilms on host surfaces promote adherence and persistence on mucosal tissues, provide protection from host defenses and antibiotics, and represent a primary source of chronic disease. Importantly, multiple studies have suggested that nasopharyngeal colonization with M. catarrhalis promotes subsequent persistent colonization with the two other major otopathogens Streptococcus pneumoniae and/or nontypeable Haemophilus influenzae (NTHI), resulting in a significantly increased risk of OM. The first goal of this proposed research project is to provide a thorough understanding of the contribution of M. catarrhalis to the stable and persistent colonization of the other otopathogens, which then potentiates the development of OM. Moreover, novel therapeutic approaches designed to eradicate planktonic and biofilm-associated bacteria from the middle ear would not only significantly decrease the constant use of antibiotics in young children, it would also decrease the associated morbidity and the need to perform surgeries for insertion of tympanostomy tubes. Thus, the second goal of this research plan is to adapt photodynamic therapy (PDT) into an efficacious, noninvasive treatment for both acute and chronic OM resulting from M. catarrhalis monospecies and polymicrobial biofilms.